If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic ...
CAMBRIDGE, Mass.—Phillip A. Sharp (OTC:SHCAY), a director at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), executed a significant stock transaction, according to a recent SEC filing. On January ...
Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...
Hosted on MSN22d
Vertex's Pain Drug: Big Pharma's Next Major Success?Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...
It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much. However, there are ...
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...
In a court filing on Monday, the Department of Health and Human Services fired back at Vertex Pharmaceuticals, standing by a directive that the biotech’s proposed fertility services program to go with ...
Pam Bondi is likely to sail to confirmation—even if she's an election denier and pretends she was born yesterday—because she meets the simple qualifications of being a lawyer and former prosecutor, ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 3.06% to $424.26 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...
Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given its dominance in the cystic fibrosis treatment category and diversified pipeline, making a compelling case ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback